CRL Insider Shannon M Parisotto Sells $743K of Stock

Shannon M Parisotto, Corporate Executive Vice President of Discovery and Safety Assessment at Charles River Laboratories International, Inc. CRL, sold 2,156 shares of the company on October 21, 2026. According to a Form 4 filed with the Securities and Exchange Commission, the shares were sold at a price of $344.41 each, for a total value of $742,547.96.

CRL Charles River Laboratories International, Inc.

$345.37 ▲ +70.62% year to date

1M 3M YTD

Daily close · Oct 23, 2026

Inside Shannon M Parisotto's Charles River Trade

The sale was executed under a pre-arranged Rule 10b5-1 trading plan. Parisotto's latest transaction marks her second reported sale in the stock since August, following an earlier disposal on October 5. Following this transaction, she holds 4,807 shares in the company, representing an approximate 30.96% reduction in her personal holdings.

Other Institutional Activity in Charles River Laboratories

Large funds continue to adjust their positions in the healthcare services provider. Harris Associates L.P. grew its holdings by 87,854 shares, ending with 2,241,144 shares worth $774,023,892. Allspring Global Investments Holdings, LLC reduced its stake by 88,106 shares to finish with 1,905,247 shares valued at $658,015,147. Ariel Investments, LLC increased its stake by 61,957 shares to hold 1,506,185 shares worth $520,191,106. Earnest Partners trimmed its holdings by 16,893 shares, leaving it with 971,366 shares worth about $220,296,089. Gotham Asset Management expanded its position by adding 68,986 shares, bringing its total to 358,502 shares valued at roughly $67,419,885.

Charles River Laboratories International, Inc. Stock Down 1.5%

On the day of the transaction, Charles River stock closed at $344.87. As of October 23, 2026, the stock recently traded around $339.66, which is down about 1.5% from that event close. The shares sit roughly 3.3% below their 52-week high of $351.21 and well above their 52-week low of $146.20.

Recent Earnings

Charles River Laboratories reported trailing twelve-month revenue of $3,998,987,008 with a negative earnings per share of $4.80. The company recorded a net margin of -6.0% and a return on equity of -7.5%. Its year-over-year revenue growth stood at -2.7%. The firm is scheduled to release its next financial update on November 4, 2026.

Insider Buying and Selling at Charles River Laboratories International, Inc.

Insider transactions over the past few months included multiple sales by key leaders. Director James C Foster sold 33,561 shares on August 25, 2026, at $300.00 per share for a total of $10,068,300. Director Nancy C Andrews sold 573 shares on August 18, 2026, at $285.24 per share valued at $163,443. Shannon M Parisotto also sold 2,039 shares on August 19, 2026, at $294.12 per share, and an additional 981 shares on October 5, 2026, at $308.44 per share.

Analysts Set New Price Targets

Wall Street firms updated their outlooks through September and October. Deutsche Bank, TD Cowen, and Jefferies all maintained buy ratings with varying price targets. Morgan Stanley maintained its overweight rating on October 13, 2026, while Evercore ISI Group kept an outperform rating. The stock carries a consensus buy rating with a mean price target of $313.79 across 14 analyst opinions.

About Charles River Laboratories

Headquartered in Wilmington, Massachusetts, Charles River Laboratories supports the biopharmaceutical industry by providing essential products and services for drug discovery and preclinical development. Its offerings include research animal models, safety assessment services, and laboratory support that help researchers advance new therapies.

Bottom Line

Investors will watch the upcoming earnings report on November 4, 2026, for further updates on financial performance and demand across research services. Regulatory filings will continue to track executive trading activity.